Related Experiment Video
Updated: Sep 28, 2025

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials
Shibani Nicum1, Sarah P Blagden2
1Department of Oncology, University College London Cancer Institute, London, United Kingdom.
Abstract:
PARP inhibitors have revolutionized the management of ovarian cancer and are being licensed for other cancer indications. The clinical trials prompting licensing decisions in ovarian cancer were dominated by White participants, or participant ethnicity was not documented. To compensate for this, replicative studies like L-MOCA can be run in specific ethnic groups. In the future, strategies such as mandatory collection and publication of race and ethnicity data are essential alongside concerted efforts to widen the inclusivity of trial recruitment. See related article by Gao et al., p. 2278.
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Diversity in Cell Signaling Responses
Graded and Abrupt Responses
Some signaling systems generate...

